Delivery Order SPE2DB22D2206-SPE2DB25FJC69
- Not listed
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,779.72 for 90 tablets of Gemtesa 75 mg on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity) with a ceiling value of $8,291.23. This firm fixed-price delivery order, with an ultimate completion date of August 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $7,558.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The contract was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $42,751.81. This non-set-aside delivery order is expected to be completed by August 1, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency has awarded a delivery order valued at $10,816.44 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a $10,738.28 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract executed on July 21, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a $19.2K delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity), with completion scheduled for July 30, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $12,290.03 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive delivery order utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order valued at $43,249.13 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count packages) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used in the treatment of overactive...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC69Delivery Order
The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to supply comprehensive pharmaceutical products, including brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for Gemtesa, a medication used in the treatment of overactive bladder, reflects the company's ongoing role in fulfilling federal medical supply requirements for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 7/28/25 |